Is hyperlipazemia a poor prognostic factor in patients with COVID-19 ?

Authors : Orhan COŞKUN, Mustafa ÇAPRAZ, Mustafa CİHANGİROĞLU, Ahmet Turan KAYA

Pages : 720-725

Doi:10.32322/jhsm.1057456

View : 26 | Download : 13

Publication Date : 2022-05-30

Article Type : Research Paper

Abstract :Introduction: COVID-19 disease may pose a considerable health threat to healthy individuals and individuals with comorbidity. The SARS-CoV-2 virus affects the respiratory tract and may cause damage to the pancreas by binding to the ACE-2 receptor in the pancreas. In our study, we investigated the effects of hyperlipasemia on morbidity and mortality in patients diagnosed with COVID-19. Material and Method: In this study, 2350 patients diagnosed with COVID-19 between November 2020 and December 2020 were retrospectively reviewed. Other possible causes of hyperlipasemia were excluded. Hyperlipasemia secondary to COVID-19 was detected in 338 patients. These patients were divided into two groups based on their lipase elevation rates. Results: Hyperlipasemia was detected in 14.4% of the patients diagnosed with COVID-19, and severe hyperlipasemia insert ignore into journalissuearticles values(>3x); was detected in 2.3%. The mean age of the patients was 64±13.8 insert ignore into journalissuearticles values(18-92);, of which 59.5% insert ignore into journalissuearticles values(201); were male. In our study, 24 patients insert ignore into journalissuearticles values(1%); were diagnosed with acute pancreatitis. When compared according to lipase level, a significant difference was found between the groups regarding the history of HT, CCI score, development of ARF at follow-up, development of ARDS, need for ICU hospitalization, need for intubation, length of stay in ICU, and death rates. A weak correlation was found in the correlation analysis between hyperlipasemia and ARDS development and mortality. Conclusion: Elevated lipase levels were associated with poor prognosis and mortality in patients with COVID-19 infection.
Keywords : SARS CoV 2, hyperlipasemia, COVID 19, pancreatitis, viral pancreatitis